REDESIGNING ANTIBODY DRUGS FROM THE GROUND UP
Xencor is expanding the therapeutic boundaries of monoclonal antibody drugs. Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases. Nine programs are in clinical testing and many more are in preclinical development.
XmAb Fc domains can be substituted into nearly any antibody, creating the basis for numerous partnerships.
Diversified Antibody Drug Pipeline
Our unique portfolio of XmAb-engineered Fc domains enable highly selective immune-modulators and targeted cancer therapies.
Unleashing Bispecific Antibodies
Our technology can simultaneously address multiple disease targets while improving half-life, stability and ease of manufacturing.
Xencor is a publically traded company on the NASDAQ stock exchange under the symbol XNCR.
Access the latest information for shareholders
Xencor Provides Updates on Lead Programs and Reviews Bispecific Oncology Partnership; Announces Expansion of Bispecific Oncology Pipeline at Analyst Day
BioWorld Today | Terrific bispecifics crash CAR T party: Watch data mature, says Xencor CEO
Access the most recent scientific and investor presentations
Xencor, Inc. Headquarters
111 West Lemon Avenue,
Monrovia, CA 91016
Xencor, Inc. San Diego
12770 High Bluff Drive, Suite 260
San Diego, CA 92130